Navigation Links
Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level
Date:12/1/2008

GOTHENBURG, Sweden, December 1 /PRNewswire/ -- Mentice proudly announces the launch of two new products for endovascular simulation training - the Mentice VIST 7.7 enhanced training modules for Carotid and Coronary interventions. New features such as vital signs, complications, medication management and measurement functionality add to the clinical realism and enhance the educational value of simulation training.

"Features like vital signs and complications imply a dynamic patient representation which requires further decision making, planning and patient interactions," said Goran Malmberg, President/CEO of Mentice.

"On top of the new functionalities, we are launching new anatomical content and further training alternatives such as CTO (Chronic Total Occlusion) lesions and cases that enable transradial access," Malmberg continues. "This launch truly shows that Mentice continues to be a driver of the medical simulation market and it further strengthens our position as a leader in the field of endovascular simulation training."

With the launch of the VIST 7.7 training modules Mentice adds to the already wide range of training opportunities for Carotid and Coronary interventions - all together a total of 42 patient cases. A summary of the new features are presented below.

Vital signs - All cases have vital signs recognition and response.

Complications - A select number of cases include complications that will occur as a result of user actions. One example, engaging a catheter too deeply into an ostium may result in vascular spasm.

Medication management - Medication administration is included to manage the complications the trainees encounter. One example of this would be the injection of Nitroglycerin for treatment of a spasm.

Measurement functionality - New measurement functionality has been added to allow the users to easily measure the diameters and length of lesions, reference vessels, etc - adding additional realism to the equipment selection process.

Mentice - improving patient safety

Mentice is a world leader in medical simulation, providing qualified solutions for training, education and assessment opportunities. With a focus on minimally invasive techniques and procedures, Mentice develops simulation systems for training in a safe environment within the fields of endovascular intervention and endoscopic surgery. The advantages of training with Mentice solutions are well documented enhancing clinical performance, reducing cost, and, in the long term, improving patient safety.

    For further information, please contact
    Goran Malmberg, President/CEO of Mentice.
    Office: +46-31-33-99-401,
    Web:http://www.mentice.com


'/>"/>
SOURCE Mentice AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mentice, Inc. Announces Appointment of Vice-President, Sales and Marketing, Americas
2. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
3. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
4. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
5. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
6. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
7. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
8. NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information
9. Brookdale Senior Living Announces Enhanced Web Site
10. T cell immunity enhanced by timing of interleukin-7 therapy
11. The HealthCentral Network and Sister to Sister Form Alliance to Develop Enhanced Online Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo reveals ... of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily ... from a variety of flip book animations. In Addition, users can modify each preset ...
(Date:12/7/2016)... ... December 07, 2016 , ... Bioelectronic ... Plus for consumers and healthcare professionals to manage chronic and acute pain. ... treatment modalities available in a single device. The announcement is part of ...
(Date:12/7/2016)... ... 2016 , ... “The Road To Restoration”: an informative and enlightening book ... a week showing of hands. “The Road To Restoration” is the creation of published ... with the brass ring that you could reach out for, and grab, on the ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons ... will inspire the reader to be aware of God's direction in their lives. “Walking ... Sanford Smith, retired teacher and active church leader. , Sanford says, “I ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... Dec. 6, 2016  Viking Therapeutics, Inc. ("Viking") ... company focused on the development of novel therapies ... the U.S. Food and Drug Administration (FDA) has ... treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a ... that selectively regulates the expression of genes believed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
Breaking Medicine Technology: